SCHEDULE: Gueck Discloses 5% Stake in Mesoblast Ltd.
Beneficial Ownership Report
Dr. William J. Gueck has reported a 5% beneficial ownership stake in Mesoblast Ltd., primarily through shared voting and dispositive power over various trusts and holding companies.
Summary
- Dr. William J. Gueck reported beneficial ownership of 64,521,900 Ordinary Shares of Mesoblast Ltd. as of September 12, 2025.
- This represents approximately 5.0% of the company's 1,281,167,187 Ordinary Shares outstanding as of August 25, 2025.
- Gueck holds sole voting and dispositive power over 525,000 Ordinary Shares held in the form of American Depositary Receipts (ADRs).
- He holds shared voting and dispositive power over 63,996,900 Ordinary Shares held in the form of ADRs.
- The shared ownership includes shares held by Conrad Gueck, Ava Gueck, the Mary DeAnn Gueck trust (where Dr. Gueck is trustee), the William Gueck trust (where Mary DeAnn Gueck is trustee), Cova Holdings LP, and AVCO Holdings LP.
- Cova Holdings LP's beneficial ownership includes 350,000 Ordinary Shares underlying warrants exercisable within 60 days.
Sentiment
Score: 6
Explanation: The filing is a neutral disclosure of a significant ownership stake. While a 5% stake can be seen as a positive sign of investor confidence, the filing itself does not contain operational news or forward-looking statements to significantly shift sentiment. The disclaimer regarding beneficial ownership for certain entities adds a slight nuance.
Positives
- A significant individual investor, Dr. William J. Gueck, has disclosed a 5% beneficial ownership stake, indicating a notable investment in Mesoblast Ltd.
Risks
- Dr. William J. Gueck expressly disclaims beneficial ownership of shares held by Cova Holdings LP and AVCO Holdings LP for purposes of Section 13(d) of the Act, which could imply a nuanced control structure or potential future disputes over actual control.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake by an individual investor, Dr. William J. Gueck, in Mesoblast Ltd. It does not provide specific operational or strategic updates that would directly relate to broader industry trends or competitors, beyond indicating an investor's confidence in the company within its sector.
Stakeholder Impact
- Shareholders: The disclosure of a 5% beneficial ownership by Dr. William J. Gueck provides transparency regarding a significant investor's position, which could influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-08-25 | Date used to calculate outstanding shares (1,281,167,187) based on issuer information. |
| 2025-09-12 | Date of event requiring the filing of this statement and the date as of which the reporting person's ownership is reported. |
| 2025-09-16 | Date the Schedule 13G was signed and filed. |
Keywords
Mesoblast Ltd, MESOBLAST, MSB, Schedule 13G, Beneficial Ownership, William Gueck, ADRs, Shareholder, Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.